leon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulation

EQS-News: leon-nanodrugs GmbH / Key word(s): Financing/Financing leon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulation 06.08.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. leon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulation

Munich (Germany), August 6, 2024 – leon-nanodrugs GmbH (LEON), a pharmatech company specializing in the development of nanoencapsulation systems for genetic material and other active substances, announced today the closing of a Series D financing round. New lead investor LBBW Venture Capital closed the round together with new investors and existing shareholders like Albany Private Equity Holdings Pty Ltd., CD-Venture GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Partners, TVM Life Science Innovation I L.P., and others.

“I am very pleased that we have completed this financing in the planned amount. The new funds will be used to augment the product portfolio. Our portfolio of leading equipment is designed to serve the Cell & Gene Therapy industry, enabling highly economic GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Together with the financing, this puts us in a good position to select the best possible strategic partner to bring those products to the market”, commented Christian Nafe, Managing Director & CFO of LEON.

LEON’s strongly differentiated systems offer significant USP’s filling current industry gaps:

- NANOscreen: bench-top system for simplified formulation screening
- NANOlab : bench-top system for fast and efficient process development
- NANOme : aseptic production system for high throughput small- and individualized-scale GMP manufacturing requiring no cleaning and sterilization due to a single use component
- NANOus : large scale production unit for commercial, sterile GMP batches.

The underlying FR-JET reactor technology is prepared for future versatility of carrier material, and is optimized for minimal batch losses, and no scaling out. It is included in all NANO-systems allowing to seamlessly scale up from process development to commercial manufacturing.